[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354575-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354575-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-in-aptamer-diagnostics-targeting-non-small-cell-lung-cancer-a-systematic-review","Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer - A Systematic Review","","Non-small-cell lung cancer (NSCLC) remains one of the most common cancers and a leading cause of cancer mortality worldwide, making early diagnosis, prognosis, and targeted therapy high-priority research. Aptamers are single-stranded DNA/RNA ligands generated by SELEX, enabling high-affinity and specific binding with easy modification to improve half-life while avoiding immunogenicity and toxicity. This systematic review summarizes DNA and RNA aptamer-based diagnostic molecules for NSCLC, covering all studies from 2000 onward.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-aptamer-diagnostics-targeting-non-small-cell-lung-cancer-a-systematic-review/354575/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-aptamer-diagnostics-targeting-non-small-cell-lung-cancer-a-systematic-review/354575.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the goal of this systematic review on NSCLC diagnostics?","Question",{"text":63,"@type":64},"It summarizes current knowledge on DNA and RNA aptamer-based molecules for NSCLC diagnosis, based on studies included from 2000 onward.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are aptamers generated and why are they considered useful for NSCLC diagnosis?",{"text":68,"@type":64},"Aptamers are single-stranded DNA or RNA produced by SELEX, allowing high-affinity, high-specificity binding and enabling modification to enhance target binding and half-life without immunogenicity or toxicity.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges still limit the clinical application of aptamers in NSCLC diagnosis?",{"text":72,"@type":64},"Application is still early, largely due to limited literature, the dominance of antibodies in the pharmaceutical market, and difficulties in target identification.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354575,1790561354,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":99,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nAdvances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review  \nLisa Agnello 1, *,†, Ilaria Leone 1,†, Alessandra Affinito 1, Carla Lucia Esposito 2, Silvia Catuogno 2, Anna D’Agostino 1, *, Marco Salvatore 1, Gerolama Condorelli 2,3,‡ and Silvia Nuzzo 1,‡  \nAcademic Editor: Eric Santoni-Rugiu  \nReceived: 26 June 2026  \nRevised: 23 July 2026  \nAccepted: 28 July 2026  \nPublished: 3 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 IRCCS SYNLAB SDN, 80146 Naples, Italy; [ilaria.leone@synlab.it](ilaria.leone@synlab.it) (I.L.); alessandra.affinito@synlab.it (A.A.); [marco.salvatore@synlab.it](marco.salvatore@synlab.it) (M.S.); [nuzzo.silvia@gmail.com](nuzzo.silvia@gmail.com) (S.N.)  \n2 Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”(IEOMI), Consiglio Nazionale delle Ricerche (CNR), 80146 Naples, Italy; c.esposito@cnr.ieos.it (C.L.E.); [s.catuogno@ieos.cnr.it](s.catuogno@ieos.cnr.it) (S.C.); [gecondor@unina.it](gecondor@unina.it) (G.C.)  \n3 Department of Molecular Medicine and Medical Biotechnology,“Federico II” University of Naples,  \n80146 Naples, Italy  \n* Correspondence: [lisa.agnello@synlab.it](lisa.agnello@synlab.it) (L.A.); [anna.dagostino@synlab.it](anna.dagostino@synlab.it) (A.D.)† These authors contributed equally to this work.  \n‡ These authors also contributed equally to this work.  \nAbstract  \nNon-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. For this reason, initial diagnosis, prognosis, and targeted therapy of NSCLC represent very attractive areas of study. Aptamers are single-stranded nucleic acids (RNA or DNA) generated through Systematic Evolution of Ligands by Exponential Enrichment (SELEX); they are able to bind to a molecular target with high affinity and specificity. Thanks to their intrinsic nucleic acid properties, they can be easily modified and optimized to enhance target binding and their half-life; moreover, they exhibit no immunogenicity and toxicity. Due to this, many aptamers have just been selected against NSCLC biomarkers and provide specific imaging agents to improve the diagnosis of this type of cancer. However, despite the promising results in preclinical studies, the application of aptamers in NSCLC diagnosis is still in its early stages, mainly due to the limited literature in the research world, the dominance of antibodies in the pharmaceutical market and the challenge of target identification. Consequently, this appears to be a temporary issue, and aptamers could see increasing application in the future; thus, we performed a review aimed at summarizing current knowledge on the new promising DNA and RNA aptamer-based molecules for NSCLC diagnosis. All studies from 2000 were included and investigated. Our findings showed that several DNA and RNA aptamers are promising diagnostic tools for NSCLC management.  \nKeywords: aptamer; diagnostic; NSCLC; liquid biopsy; detection; fluorescence; exosome; CTC; protein  \n1. Introduction  \nCancer detection provides a wide range of strategies designed to identify tumor cells or neoplastic lesions at an early stage. Over the past decades, diagnostic approaches have been switched from simple morphological observations to advanced live imaging techniques. In this specific case, non-small cell lung cancer (NSCLC) represents the most common cause of cancer-related deaths [1] and is diagnosed at an advanced stage [2] through a  \nprocess that integrates several clinical, radiological, and laboratory steps. In most cases, initial suspicion arises from the presence of symptoms that lead to further investigations such as techniques based on computed tomography (CT), useful for clarifying the extent of the disease.  \nA definitive diagnosis,","cbCaibtJnYfN60Nf","https://ap.wps.com/l/cbCaibtJnYfN60Nf","pdf",563898,24,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is the goal of this systematic review on NSCLC diagnostics?\",\"answer\":\"It summarizes current knowledge on DNA and RNA aptamer-based molecules for NSCLC diagnosis, based on studies included from 2000 onward.\"},{\"question\":\"How are aptamers generated and why are they considered useful for NSCLC diagnosis?\",\"answer\":\"Aptamers are single-stranded DNA or RNA produced by SELEX, allowing high-affinity, high-specificity binding and enabling modification to enhance target binding and half-life without immunogenicity or toxicity.\"},{\"question\":\"What challenges still limit the clinical application of aptamers in NSCLC diagnosis?\",\"answer\":\"Application is still early, largely due to limited literature, the dominance of antibodies in the pharmaceutical market, and difficulties in target identification.\"}]","Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer - A Systematic Review | PDF",1790112235,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/908a038ab8c5fd12313856a024383b59.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cefd6d7cf0e34c2363220647d832344.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e206870f4a20851de19045408531e489.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cd646323036e0b3a5444728c00b33cc.webp",980,1385]